Quantitative structure-in vivo half-life relationships of perfluorochemicals for use as oxygen transporters.

Yamanouchi, Kouichi; Tanaka, Mikio; Tsuda, Yoshio; Yokoyama, Kazumasa; Awazu, Shoji; Kobayashi, Yoshiro

doi:10.1248/cpb.33.1221

Cited by 35 publications

(21 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 1 illustrates the total bromine content in the RES (liver + spleen) following intravenous inhsion of a 90/10 w/w PFOBPFDB emulsion at a dose of 5.4 g PFC/kg. The small tilled circles are data from Yamanouchi et al [7]. A double exponential pharmacokinetic model (Minsq 11, MicroMath Inc.) was used to fit the data.…”

Section: Resultsmentioning

confidence: 99%

Room Temperature Stable Perfluorocarbon Emulsions with Acceptable Half-Lives in the Reticuloendothelial System

Weers¹,

Liu²,

Fields³

et al. 1994

Artificial Cells, Blood Substitutes, and Biotechnology

View full text Add to dashboard Cite

Prolonged room temperature stability (i.e. zero particle growth) can be achieved for concentrated emulsions of perflubron (perfluorooctyl bromide) or perfluorodecalin via addition of a secondary high molecular weight, lipophilic fluorocarbon component. Due to their enhanced lipophilic character, the secondary fluorocarbon components have acceptable half-lives in the organs of the reticuloendothelial system.

show abstract

Section: Resultsmentioning

confidence: 99%

Room Temperature Stable Perfluorocarbon Emulsions with Acceptable Half-Lives in the Reticuloendothelial System

Weers¹,

Liu²,

Fields³

et al. 1994

Artificial Cells, Blood Substitutes, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…24) Therefore, the disappearance of parenchymal contrast 24 h after injection is considered a result of dissolution of gas and simultaneous shrinkage of the microbubbles staying in the liver parenchyma. As it has been postulated so far that the parenchymal contrast might be due to the accumulation of the microbubbles in Kupffer cells in the liver, a faster disappearance of vessel enhancement suggested that the microbubbles might be more stable in the cells than in the blood stream.…”

Section: Discussionmentioning

confidence: 99%

Gray-Scale Liver Enhancement with Sonazoid (NC100100), a Novel Ultrasound Contrast Agent; Detection of Hepatic Tumors in a Rabbit Model

Watanabe

Matsumura

Chen

et al. 2003

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The liver contrast effects of Sonazoid in two ultrasonographic imaging modes, gray-scale conventional and harmonic, were examined as a time-related study in normal rabbits, and evaluated quantitatively and visually with tumor-model rabbits to estimate the diagnostic potential. Peak enhancement of vessels and parenchyma was observed 1 min after injection in both modes, although signal enhancement in the parenchyma lasted for 120 min compared with rapid decay (5-10 min) in vessels. When Sonazoid was intravenously injected into metastatic carcinoma-model (VX-2) rabbits, all hepatic tumors showed ring enhancement in the early phase followed by clear contrast defects in the delayed phase, because signal enhancement remained only in normal parenchyma. Visual analysis scores for the diagnosis of tumors were improved by Sonazoid injection, and the videodensitometric differences between tumor and normal tissues were significantly greater after injection. Although the harmonic mode tended to show better contrast effects, the conventional mode provided significant contrast enhancement in this hepatic tumor-model. Sonazoid might be useful for the detection of undifferentiated tumors in the liver by making it possible to visualize neovascularity in the early phase and clear contrast defects in the delayed phase, not only in the harmonic but also in the conventional mode.

show abstract

“…Although systematic cellular uptake studies with a structurally diverse group of PFCs have not been performed to date, it is likely that their uptake into cell membranes increases with increasing lipophilicity. This hypothesis is indirectly supported by the observation that the elimination of PFCs, which occurs primarily via the lung [54], is directly proportional to their lipophilicity and, thus, their uptake by cells in the lung [55]. The lipophilicity of (nonfunctionalized) PFCs is highly dependent on their molecular structure and decreases in the order: tricyclic > bicyclic > monocyclic > aliphatic [56]; whereas the introduction of polarizable functional groups, such as bromine, significantly increases the lipophilicity of PFCs [57].…”

Section: Cellular Uptake Of Pfcs By Passive Diffusionmentioning

confidence: 92%

Anti-inflammatory effects of perfluorocarbon compounds

Lehmler¹

2008

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Perfluorocarbon compounds (PFCs) are of interest for the treatment of acute lung injury due to unique physicochemical properties such as high solubility for oxygen. Different respiratory treatment modalities (e.g., liquid ventilation or aerosolized PFCs) have been shown to decrease pulmonary inflammatory responses in addition to improving lung compliance in animal models of lung injury and in clinical trials. Specifically, PFC-based treatment modalities have been shown to reduce levels of cytokines, chemokines and other mediators of pulmonary inflammation in a PFC- and, to some extent, concentration-dependent manner. As a result, neutrophil adhesion, accumulation and activation are reduced in PFC-treated animals and in humans undergoing partial liquid ventilation. Although more fundamental studies of the underlying anti-inflammatory mechanisms are needed, respiratory treatment modalities involving PFCs hold great clinical promise.

show abstract

Quantitative structure-in vivo half-life relationships of perfluorochemicals for use as oxygen transporters.

Cited by 35 publications

References 2 publications

Room Temperature Stable Perfluorocarbon Emulsions with Acceptable Half-Lives in the Reticuloendothelial System

Room Temperature Stable Perfluorocarbon Emulsions with Acceptable Half-Lives in the Reticuloendothelial System

Gray-Scale Liver Enhancement with Sonazoid (NC100100), a Novel Ultrasound Contrast Agent; Detection of Hepatic Tumors in a Rabbit Model

Anti-inflammatory effects of perfluorocarbon compounds

Contact Info

Product

Resources

About